C. Bale

Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial

Peter Aaby, Cesário Martins, M.‐L. Garly et al. · BMJ · 2010 · 284 citations · Full text

Veterinary Medicine, Child Health, Pediatrics +17

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2020 · 227 citations · Full text

Medicine, Oncology, Pharmacology +17

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Sacha J. Howell, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2022 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial

Cesário Martins, M.‐L. Garly, C. Bale et al. · BMJ · 2008 · 71 citations · Full text

Medicine, Child Health, Pediatrics +17